Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Akeso's gumokimab approved in China
Business drug approval

Akeso's gumokimab approved in China

Analysis based on 7 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026

Sentiment
70
Attention
4
Articles
7
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The approval of Gumokimab by the China — National Medical Products Administration is expected to positively impact Akeso's stock price due to the expansion of its product portfolio and potential revenue generation. This also signifies a positive development for the pharmaceutical industry in China, offering a new treatment option for a significant patient population.

Pharmaceuticals Biotechnology
Event Summary

Akeso announced that the China — National Medical Products Administration of China has approved Gumokimab (AK111), its internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis. The approval was based on pivotal Phase III clinical study results demonstrating Gumokimab's rapid and robust efficacy, durable complete skin clearance, and favorable safety and dosing profile. The drug achieved a PASI 75 response rate of 94.6% and a PASI 100 response rate of 47.7% at Week 12, with durable clearance through Week 52. Professor Xu Jinhua and Dr. Xia Yu highlighted the drug's potential to address unmet needs for the approximately 6.7 million psoriasis patients. Additionally, a supplemental New Drug Application for Gumokimab in active ankylosing spondylitis has been accepted for review by the United States — Center for Drug Evaluation and Research.

Key Actions
100 China — National Medical Products Administration approved Gumokimab
90 Akeso developed Gumokimab
60 United States — Center for Drug Evaluation and Research accepted for review Gumokimab
Entities Involved
stock
Akeso
Akeso received NMPA approval for Gumokimab, strengthening its autoimmune disease portfolio and global competitiveness. This approval is a significant milestone for the company, enhancing its market position and offering a new treatment option for psoriasis patients.
Importance 100 Sentiment 80
oth
Gumokimab
Gumokimab, an anti-IL-17 monoclonal antibody developed by Akeso, received NMPA approval for moderate-to-severe plaque psoriasis, demonstrating rapid and robust efficacy, durable skin clearance, and a favorable safety profile.
Importance 95 Sentiment 75
govactor
China — National Medical Products Administration
The China — National Medical Products Administration approved Gumokimab, enabling its commercialization in China and providing a new treatment option for patients with moderate-to-severe plaque psoriasis.
Importance 80 Sentiment 0
cnt
China
China is the country where the China — National Medical Products Administration operates and where Gumokimab has been approved for market, impacting its healthcare sector and patient population.
Importance 50 Sentiment 0
per
Xia Yu
Xia Yu, Founder, Chairwoman, President and CEO of Akeso, expressed gratitude to the study participants and highlighted Akeso's growing portfolio in autoimmune diseases.
Importance 40 Sentiment 0
per
Xu Jinhua
Xu Jinhua is the Principal Investigator of the pivotal Phase III registration study for Gumokimab, providing expert commentary on its efficacy and importance for psoriasis patients.
Importance 30 Sentiment 0
govactor
United States — Center for Drug Evaluation and Research
The United States — Center for Drug Evaluation and Research accepted a supplemental New Drug Application for Gumokimab in active ankylosing spondylitis, indicating potential future market expansion for the drug.
Importance 30 Sentiment 0
oth
Ebdarokimab
Ebdarokimab is another therapy developed by Akeso, complementing Gumokimab in addressing diverse patient needs in autoimmune diseases.
Importance 20 Sentiment 0
oth
Manfidokimab
Manfidokimab is an Akeso drug advancing in late-stage development across multiple indications, contributing to the company's immunology and inflammation platform.
Importance 15 Sentiment 0
oth
AK139
AK139 is Akeso's first-in-class IL-4R/ST2 bispecific antibody, rapidly progressing in development and enhancing Akeso's immunology and inflammation platform.
Importance 15 Sentiment 0
oth
Huashan Hospital
Huashan Hospital is where Professor Xu Jinhua conducted the pivotal Phase III study for Gumokimab.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.